Genmab AS (OCSE:GMAB) Cyclically Adjusted PB Ratio: (As of Aug. 08, 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

OCSE:GMAB Genmab AS OCSE:GMAB
100 GF Score
Price kr1,999.00
GF Value kr2,317.70
Valuation Modestly Undervalued
! 5 Warning Signs
View Full Analysis

What is Genmab AS Cyclically Adjusted PB Ratio?

Shiller PE for Stocks: The True Measure of Stock Valuation


Genmab AS  (OCSE:GMAB) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Genmab AS Cyclically Adjusted PB Ratio Related Terms


Genmab AS Cyclically Adjusted PB Ratio Historical Data

* Premium members only.

The historical data trend for Genmab AS's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Genmab AS Cyclically Adjusted PB Ratio Chart

Genmab AS Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 22.49 17.79 10.22 5.69 6.34

Genmab AS Quarterly Data
Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26 Jun26
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 4.50 6.27 6.34 5.12 0.00

OCSE:GMAB vs VRTX, REGN, RVMD: Cyclically Adjusted PB Ratio Comparison

For the Biotechnology subindustry, Genmab AS's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Genmab AS Cyclically Adjusted PB Ratio vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Genmab AS's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Genmab AS's Cyclically Adjusted PB Ratio falls into.


OCSE:GMAB
100GF Score
Genmab AS OCSE:GMAB
Cyclically Adjusted PB Ratio is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Genmab AS Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Genmab AS's Cyclically Adjusted Book per Share for the quarter that ended in Jun. 2026 is calculated as:

For example, Genmab AS's adjusted Book Value per Share data for the three months ended in Jun. 2026 was:

Adj_Book=Book Value per Share/CPI of Jun. 2026 (Change)*Current CPI (Jun. 2026)
=626.513/122.9700*122.9700
=626.513

Current CPI (Jun. 2026) = 122.9700.

Genmab AS Quarterly Data

Book Value per Share CPI Adj_Book
201609 65.352 100.200 80.203
201612 79.944 100.300 98.013
201703 82.491 101.200 100.236
201706 90.784 101.200 110.313
201709 88.502 101.800 106.907
201712 104.053 101.300 126.312
201803 106.472 101.700 128.740
201806 110.815 102.300 133.205
201809 114.862 102.400 137.935
201812 131.293 102.100 158.130
201903 131.206 102.900 156.797
201906 135.672 102.900 162.134
201909 191.279 102.900 228.587
201912 218.131 102.900 260.676
202003 221.135 103.300 263.243
202006 273.865 103.200 326.329
202009 281.591 103.500 334.563
202012 295.459 103.400 351.379
202103 302.680 104.300 356.861
202106 304.858 105.000 357.032
202109 321.000 105.800 373.094
202112 338.376 106.600 390.339
202203 350.217 109.900 391.867
202206 368.046 113.600 398.403
202209 402.326 116.400 425.035
202212 421.840 115.900 447.573
202303 424.249 117.300 444.756
202306 441.697 116.400 466.628
202309 471.413 117.400 493.779
202312 490.352 116.700 516.697
202403 495.032 118.400 514.139
202406 485.686 118.500 504.007
202409 505.732 118.900 523.043
202412 575.798 118.900 595.508
202503 576.839 120.200 590.132
202506 557.588 120.700 568.075
202509 593.997 121.600 600.689
202512 605.440 121.200 614.282
202603 598.391 121.680 604.735
202606 626.513 122.970 626.513

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.

Is Genmab AS (OCSE:GMAB) Overvalued in 2026?

Based on GuruFocus' analysis, Genmab AS stock appears to be undervalued. The current stock price of kr1,999.00 is trading 13.8% below its estimated GF Value™ of kr2,317.70. GuruFocus considers Genmab AS to be Modestly Undervalued.

Key valuation signals for OCSE:GMAB:

  • Cyclically Adjusted PB Ratio:
  • GF Value™: kr2,317.70 vs. price of kr1,999.00 (13.8% below fair value)
  • GF Score™: 100/100 with 5 warning signs

No single metric tells the full story. See the OCSE:GMAB stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Genmab AS Business Description

Address Carl Jacobsens Vej 30, Valby, DNK, 2500
Genmab is a Copenhagen-based biotechnology company specializing in antibody therapeutics for the treatment of cancer. Genmab's proprietary antibody technologies are DuoBody, HexaBody, DuoHexaBody, and HexElect. Johnson & Johnson partnered with Genmab to create Darzalex, which is regarded as the standard of care for multiple myeloma and is Genmab's leading product. Genmab also has Tepezza for thyroid eye disease (partnered with Horizon), Kesimpta for relapsing multiple sclerosis (partnered with Novartis), Rybrevant (partnered with Johnson & Johnson) for non-small cell lung cancer (NSCLC), Tivdak (partnered with Seagen) for cervical cancer, and Epkinly (partnered with AbbVie) for diffuse large B-cell lymphoma. Genmab has several pipeline candidates targeting other oncologic indications.
100GF Score

Get the complete analysis for OCSE:GMAB

Cyclically Adjusted PB Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

kr1,999.00
Price
kr2,317.70
GF Value